| Objective: In this study, the proposed Chinese medicine Party " Bu Shen Yi Sui side" was used to observe the preventive effect after chemotherapy in patients with GP thrombocytopenia, highlighting Chinese medicine, " treating disease " advantage, and then provide new ideas for prevent post- chemotherapy thrombocytopenia.Method:Cancer patients affected by untreated non-small cell in Huanghua City People’s Hospital oncology and medical oncology pick Cangzhou City Hospital from January 2014- June 2015 were randomly divided into two groups according to the inclusions criteria, in which test was finally completed with a statistical significance of patients with a total of 208 cases, including 105 cases in the control group, and 103 cases in the experimental group. There is no significant difference(P> 0.05) between two groups of patients in the general information staging, chemotherapy, and other aspects of the disease into the group. All patients were given GP chemotherapy(gemcitabine 1.0g / m2 d1.8; cisplatin 25 mg / m2 d1-3) 2 cycles. Each cycle lasts for 21 days. In the control group chemotherapy was used alone to standard treatment programs, while except chemotherapy treatment, since three days before the treatment, Bu Shen Yi Sui square decoction was used in the treatment group orally until to the end of chemotherapy.Compare with the below factors in the two groups,1 Total number of patients who appears to reduce the total number of platelet and bone marrowⅢ degree of toxicity indexing and more after the 3rd and 7th day in the first cycle of chemotherapy2 Required time for patients with bone marrow toxicity degree and sub-degree Ⅲ and above to recover to normal platelet after the first cycle of chemotherapy3 Gastrointestinal reactions during the first cycle of chemotherapy4 KPS score and clinical efficacy after the end of two cycles of chemotherapy5 Comparing two groups of patients the incidence of cases of adverse reactions.Result:1 Three days after chemotherapy, 81 normal platelets cases and 22 bone marrow toxicity cases were found in treatment group, in which 2 cases with grade Ⅲ, 0 cases with Ⅳ degree, compared to the control group in the same time, 70 platelets normal risk cases, 35 bone marrow toxicity cases, including 7cases with grade Ⅲ, 2 case with Ⅳ degree. No significant difference(P> 0.05) appears while comparing bone marrow toxicity in patients, and significant difference(P <0.05) while comparing bone marrow toxicity above Ⅲ degree. Seven days after chemotherapy, 76 patients with normal platelets, and 27 patients with bone marrow toxicity, including 4cases with grade Ⅲ, 1 case with Ⅳ degree. Compared with the result in the control group at the same time, 52 cases were with normal platelets, 53 cases with bone marrow toxicity, including 14 cases with grade Ⅲ, 5 cases with Ⅳ degree. Significant difference(P <0.05) appears compared patients with bone marrow toxicity. No significant difference(P <0.01) above Ⅲ degree compared patients with bone marrow toxicity.2 Required time for chemotherapy bone marrow toxicity indexing of patients over Ⅲ in two groups after the first cycle to allow platelets returned to normal: patients in treatment group needed 5.80 ± 3.96 days, while the patients in control group needed 9.53 ± 3.16. This showed that patients in treatment group needed shorter time than control group, difference is significant(P<0.01).3 Change before and after chemotherapy happened on patients in treatment group is unknown on improve lassitude, less gas lazy words, eat less anorexia, looking not China, waist and knees, chills afraid cold, palpitations short on gas, dreams easily frightened and other symptoms. The clinical symptoms are not significant(p> 0.05). Patients in control group became worse on clinical symptoms during chemotherapy. Differences were statistically significant(P <0.05) between groups in the same time.4 Based on gastrointestinal reaction, 20 patients in treatment group got Ⅰ gastrointestinal reactions, 11 patients got Ⅱ gastrointestinal reactions, 4 patients got Ⅲ gastrointestinal reactions. In the control group, 22 patients in treatment group got Ⅰ gastrointestinal reactions, 15 patients got Ⅱ gastrointestinal reactions, 10 patients got Ⅲ gastrointestinal reactions. 1 patients got Ⅳ gastrointestinal reactions According to statistical analysis, there was significant difference P> 0.015 After the two cycles of chemotherapy, there was not significant reduce with the group KPS scores in treatment group(P> 0.05). While KPS score in the control group was significantly lower(P <0.05). There was statistically significant between the two groups(P <0.05).6 After two cycles of chemotherapy, the results of evaluation of the efficacy showed, the disease control rate(DCR) of treatment group was 75.51%, and DCR of control group was 65.12% group. Although the first one was higher, based on the statistical analysis, there was significant deference between the two groups(P<0.05).7 There were no obvious adverse reactions in patients.Conclusion:1 Chinese medicines Bu Shen Yi Sui can effectively protect platelets, prevent of chemotherapy caused the bone marrow suppression, and reduce the opportunity of bone marrow toxicity degree Ⅲ and above.2 Chinese medicines Bu Shen Yi Sui can shorten time platelet recover to normal for bone marrow suppression degree Ⅲ and above.3 Chinese medicine Bu Shen Yi Sui can prevent the development of clinical symptoms, reduce chemotherapy-induced gastrointestinal reaction rates, improve the quality of life of patients during chemotherapy, win a stable KPS, and play an active role in anti-tumor4 No obvious side effects were found in Chinese medicine Bu Shen Yi Sui, it is best to be further studied and promoted. |
PDF Full Text Request